Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Pharmaceutical Industry Salary Survey 2011
December 26, 2011
- AFII Grants France-Japan Investment Award to sanofi-aventis, Canon
December 19, 2011
- Plan Like Your Life Depended on It… It Just Might!
December 5, 2011
- Interviewing and Hiring: Strong Character Plus Good Attitude Equals Great Potential
November 14, 2011
- A Cry from the Next Generation of Japanese Pharmaceutical Executives
October 24, 2011
- The Art of Business
September 26, 2011
- NBI Increasing Efforts to Ensure Proper Use of Prazaxa
August 29, 2011
- Remicade Obtains Approval for Partial Changes in Dosage for Crohn's Disease
August 29, 2011
- Mitsubishi Chemical Medience Begins Contract Synthesis of Radiolabeled Compounds
August 29, 2011
- Emerging Markets, Japan Drove Growth in 1st Half of 2011 for Global Megapharmas
August 29, 2011
- Hisamitsu to Apply for Transdermal Oxybutynin for OAB in FY2012
August 29, 2011
- Seikagaku to Conduct Add'l Clinical Trial for SI-6603 in Japan
August 29, 2011
- Drug Wholesalers' Operating Profit Rate at Record Low 0.13% in FY2010: JPWA
August 29, 2011
- Chugai Files Application for Add'l Indication for Kytril Based on Data in Public Domain
August 29, 2011
- Kyowa Kirin Initiates PIII Trial of ARQ197 for NSCLC in Asian Countries
August 29, 2011
- Teijin Pharma, Astellas Sign New Marketing Agreement on Febuxostat
August 29, 2011
- Astellas, Kyowa Kirin Apply for Higher Doses of Amoxicillin Based on Data in Public Domain
August 29, 2011
- AnGes MG Granted Pharmaceutical Use Patent for Ets-1 in US
August 29, 2011
- Chugai Licenses Melanoma Treatment Vemurafenib from Roche; PI Trial to Begin in 2012
August 29, 2011
- Pfizer Japan Withdraws NDA for Fesoterodine
August 29, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…